Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young black African men

Hypertension

Volumn 49, Issue 4, 2007, Pages 873-877

  Melikian, Narbeh ^a   Wheatcroft, Stephen B ^c   Ogah, Okechukwu S ^a   Murphy, Cliona ^a   Chowienczyk, Phillip J ^a   Wierzbicki, Anthony S ^a   Sanders, Thomas A B ^b   Jiang, Benyu ^a   Duncan, Edward R ^a   Shah, Ajay M ^a   Kearney, Mark T ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Asymmetrical dimethylarginine; Black African; Endothelial function; NO; White European

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GLYCERYL TRINITRATE; LIPID; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROSTAGLANDIN F2 ALPHA; ARGININE; DRUG DERIVATIVE; ENZYME INHIBITOR; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CONTROLLED STUDY; ECHOGRAPHY; ESSENTIAL HYPERTENSION; EUROPEAN AMERICAN; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; VASCULAR ENDOTHELIUM; BLOOD; BLOOD FLOW; CAUCASIAN; NEGRO; PHYSIOLOGY; REGRESSION ANALYSIS; SINGLE BLIND PROCEDURE; VASODILATATION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ARGININE; BIOLOGICAL AVAILABILITY; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; NITRIC OXIDE; REGIONAL BLOOD FLOW; REGRESSION ANALYSIS; SINGLE-BLIND METHOD; VASODILATION;

EID: 34047225637     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000258405.25330.80     Document Type: Article

References (28)

1. Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233-1241.
2. Criqui MH, Vargas VV, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A, Bundens WP, Fronek A. Ethnicity and peripheral arterial disease: the San Diego Population study. Circulation. 2005;112:2703-2707.
3. Perregaux D, Chaudri AC, Rao S, Airen A, Wilson M, Sung B-H, Dandona P. Brachial vascular reactivity in blacks. Hypertension. 2000;36:866-871.
4. Kahn DF, Duffy SJ, Tomasian D, Holbrook M, Rescor L, Russel J, Gokce N, Loscalzo J, Vita JA. Effects of black race on forearm resistance vessel function. Hypertension. 2002;40:195-201.
5. Gokce N, Holbrook M, Duffy SJ, Demissie S, Cupples LA, Biegelsen E, Keaney JF Jr, Loscalzo J, Vita JA. Effects of race and hypertension on flow mediated and nitroglycerine-mediated dilation of the brachial artery. Hypertension. 2001;38:1349-1354.
6. Ganz P, Vita JA. Testing endothelial vasomotor function nitric oxide, a multipotent molecule. Circulation. 2003;108:2049-2053.
7. Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation. 2004;109:2518-2523.
8. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer M, Prasad A, Waclawiw MA, Khaled RA, Nour KRA, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
9. Cooke JP. Asymmetrical dimethylarginine: the Uber Marker? Circulation. 2004;109:1813-1819.
10. Standarisation of anthropomorphic measurements. In: Lohman T, Roche A, Martorel R, eds. The Airlie (VA) Consensus Conference. Champaign, IL: Human Kinetics; 1988:39-80.
11. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow- mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
12. Schulze F, Wesemann R, Scwedhelm E, Arakawa N, Sydow K, Albsmeier J, Ooke JP, Boger RH. Determination of asymmetric dimethylarginine (ADMA) sing a novel ELISA assay. Clin Chem Lab Med. 2004;42:1377-1383.
13. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97:1-7.
14. G-dimethyl-L- arginine in 500 subjects. Eur J Clin Invest. 2005;35:622-626.
15. O'Reilly JD, Mallet AI, McAnlis GT, Young IS, Halliwell B, Sanders TA, Wiseman H. Consumption of flavonoids in onions and black tea: lack of effect on F2-isoprostanes and autoantibodies to oxidized LDL in healthy humans. Am J Clin Nutr. 2001;73:1040-1044.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
17. Levy AS, Bosch JP, Lewis JB, green T, Rogers N, Roth D for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine. A new prediction equation. Ann Int Med. 1999;130:461-470.
18. Momin AU, Melikian N, Shah AM, Grieve DJ, Wheatcroft SB, John L, El Gamel A, Desai JB, Nelson T, Driver C, Sherwood RA, Kearney MT. Leptin is an endothelium-independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J. 2006;27:2294-2299.
19. Boger R. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38:126-136.
20. Krempl TK, Maas R, Syndow K, Boger RH, Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J. 2005;26:1846-1851.
21. Houghton JL, Philbin EF, Strogatz DS, Torosoff MT, Fein SA, Kuhner PA, Smith VE, Carr AC. The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine. J Am Coll Cardiol. 2002;39:1314-1322.
22. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthase in chronic renal failure. Lancet. 1992;339:572-575.
23. Valtonen P, Karrpi J, Nyyssonen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;828:97-102.
24. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005;10:S73-S81.
25. Asagmi T, Abbasi F, Stuehlinger M, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002;51:843-846.
26. Stühlinger MC, Abbasi F, Chu J, Lamendola C, McLaughlin T, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420-1426.
27. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Reninangiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J. 2001;65:775-778.
28. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens. 2002;15:590-593.